As a result, 12 genes were found to be downregulated following gilteritinib therapy, including CENPE, MCM4, GSPT1, MMS22L, DDX21, VDAC1, FDX1, OPA1, PDHX, ELOA, BCL3, and RACGP1, in EC, OC and GC TCGA cohort (Supplemental Fig. 4). The gene discussed is DDX21; the disease is gastric cancer.